# US 2012/0252746 A1 · Methods for Internally Controlling or Treating Equine BOT Larvae

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252746 A1
- Document ID: US20120252746A1
- Status: Published application
- Kind: A1
- Application number: 13/515,603
- Filed: 2011-01-20
- Published: 2012-10-04
- Earliest claimed: 2010-01-25
- Assignees: Eli Lilly and Company
- Inventors: Daniel Earl Snyder
- Web page: https://patentgrep.com/patent/US20120252746A1

## CPC

- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 33/00: Antiparasitic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are novel methods and formulations for orally controlling bot larvae in the gastrointestinal tract of equine animal.

## Claims

### Claim at position 1

1-23. (canceled)

### Claim 24

A method of controlling or treating bot larvae in the gastrointestinal tract of an equine animal which comprises orally administering an effective amount of a spinosyn to said animal,
wherein said spinosyn is spinosad or a physiologically acceptable salt thereof or spinetoram or a physiologically acceptable salt thereof.

### Claim 25 (depends on 24)

The method of claim 24 wherein said equine animal is a horse.

### Claim 26 (depends on 24)

The method of claim 24 wherein said spinosyn is administered with at least one other active ingredient.

### Claim 27 (depends on 24)

The method of claim 24 wherein said spinosyn is administered with a physiologically acceptable carrier.

### Claim 28 (depends on 24)

The method of claim 24 wherein said administration is carried out in a single dose.

### Claim 29 (depends on 24)

The method of claim 24 wherein said spinosyn is administered in an amount of between about 1 and 100 mg/kg of equine animal body weight.

### Claim 30 (depends on 24)

The method of claim 24 wherein said spinosyn is administered in an amount of between about 5 and 50 mg/kg of equine animal body weight.

### Claim 31 (depends on 30)

The method of claim 30 where said amount is from about 10 to about 20 mg/kg of equine animal body weight.

### Claim 32 (depends on 24)

The method of claim 24 wherein said bot larvae is Gasterophilus intestinalis, Gasterophilus nasalis, or Gasterophilus haemorrhoidalis.

### Claim 33 (depends on 32)

The method of claim 32 wherein said spinosyn is administered in an amount of between about 1 to 100 mg/kg of body weight of said equine animal.

### Claim 34 (depends on 24)

The method of claim 24 wherein said administration is in the form of a tablet, capsule, liquid, gel, paste, oral spray, buccal formulation, powder or animal feed.

### Claim 35 (depends on 24)

The method of claim 24 wherein said spinosyn is spinetoram or a physiologically acceptable salt thereof.

### Claim 36

A single-dose or pulse-dose oral formulation for controlling or treating bot larvae in the gastrointestinal tract of an equine animal, said formulation comprising an effective amount of a spinosyn, and a physiologically acceptable carrier, in an oral dosage form,
wherein said spinosyn is spinosad or a physiologically acceptable salt thereof or spinetoram or a physiologically acceptable salt thereof.

### Claim 37 (depends on 36)

The formulation of claim 36 wherein said formulation is a single-dose formulation and contains 5 to 50 mg of the spinosyn per kg of body weight of said equine animal.

### Claim 38 (depends on 36)

The formulation of claim 36 wherein said equine animal is a horse.

### Claim 39 (depends on 36)

The formulation of claim 36 wherein said formulation is suitable for administration no more than once every at least 7 days.

### Claim 40 (depends on 36)

The formulation of claim 36 which is suitable for administration not more than once every two weeks.

### Claim 41 (depends on 40)

The formulation of claim 40 which is suitable for administration not more than once every 30 days.

### Claim 42 (depends on 38)

The formulation of claim 38 wherein said formulation comprises an additional active ingredient.

### Claim 43 (depends on 39)

The formulation of claim 39 wherein said formulation contains from about 10 to about 20 mg of said spinosyn per kg of body weight of said horse.

### Claim 44 (depends on 36)

The formulation of claim 36 wherein said spinosyn is spinetoram or a physiologically acceptable salt thereof.
